Sector News

AGC Asahi Glass agrees to acquire CMC Biologics

December 21, 2016
Chemical Value Chain

CMC Biologics and AGC Asahi Glass announced today that they have entered into a definitive agreement with CMC Biologics’ shareholders, by which AGC will acquire 100% of CMC Biologics’ shares. This acquisition is expected to close in January 2017.

CMC Biologics is a global leader in clinical and commercial manufacturing of monoclonal antibodies, coagulation factors and other therapeutic proteins. AGC Asahi Glass is a world-leading manufacturer of glass, chemicals and high-tech materials.

Founded in Denmark in 2001, as a start-up company, CMC Biologics has grown to be one of the most valued independent CDMO companies in the world. Today with over 500 employees, two commercial-phase manufacturing facilities, and one early-phase manufacturing facility, CMC is one of the leaders in the biologics CDMO industry.

“With the high level of growth and success that CMC Biologics has had over the last 15 years, I am thrilled that we now will be a central part of AGC’s pharmaceutical services business, with biologic manufacturing operations in Europe, U.S.A., and Asia. AGC is a world-class company dedicated to excellence and high customer satisfaction,” said David Kauffmann, Chairman of CMC Biologics. “AGC’s commitment to best technology solutions and longtime partnership with clients align so well with CMC Biologics’ mission to be the preferred biologics CDMO service partner for the world’s top pharmaceutical and biotech companies.”

“Aligning with AGC’s success and long-term business strategy, CMC Biologics is honored to become part of AGC’s Life Science Business. We look forward to leveraging on AGC’s manufacturing expertise and existing CMO footprint, while continuing to provide innovative solutions to our clients,” said Gustavo Mahler, Chief Executive Officer of CMC Biologics. “This transaction provides the ideal ownership for CMC, as AGC fully embraces the goals of customer satisfaction, strong growth and global expansion that define our strategy.”

CMC Biologics will retain its distinct brand and independence. There are no anticipated changes in CMC operations, current leadership team or employee base. CMC Biologics continues to be fully committed to delivering the best solutions for our customers.

Source: CMC Biologics

comments closed

Related News

January 29, 2023

Dow and 3M cut thousands of jobs

Chemical Value Chain

3M and Dow have announced they are cutting thousands of roles from their global workforces in response to economic pressures. Dow has said it will cut 2,000 jobs across its global workforce (around 5%) in a bid to save US$1bn in 2023. The company says it will also cut costs by shutting down “select assets”, though it did not note where it would halt operations.

January 29, 2023

Sweden discovers Europe’s largest rare earths deposit

Chemical Value Chain

Sweden’s state mining firm has discovered what could be Europe’s largest rare earths deposit, and says it could help the bloc reduce its reliance on imports of minerals needed to manufacture clean technologies and meet climate targets.

January 29, 2023

Avantium to supply Henkel with plant-based FDCA

Chemical Value Chain

Henkel and Avantium have been partners since 2019, when Henkel joined the PEFerence consortium. This consortium of partners, coordinated by Avantium, aims to establish an innovative supply chain for FDCA and PEF (polyethylene furanoate).

How can we help you?

We're easy to reach